FST-344
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Skeletal muscle mass is not simply a product of anabolic signaling. It is equally the product of inhibitory tone – a ceiling imposed by circulating proteins that prevent unchecked growth. FST-344 is a naturally occurring isoform of follistatin, a secreted glycoprotein whose primary function is the sequestration of TGF-β superfamily ligands. Where other follistatin isoforms bind broadly across tissues, FST-344 – lacking the heparin-binding domain present in FST-315 – circulates freely in plasma and engages its targets systemically. The result is a molecule whose inhibitory reach is wide, whose biology is well-characterized, and whose therapeutic implications for muscle wasting remain an active area of inquiry.
Myostatin is the primary target, and FST-344 binds it in a stable non-signaling complex that prevents ActRIIB and ALK4/5 engagement. Natural loss-of-function myostatin phenotypes provide the clearest reference for the biological consequences of this pathway’s suppression.
Activin A and Activin B are important co-targets that FST-344 also binds with high affinity. Their inhibition extends the mechanism beyond pure myostatin neutralization and helps explain the broader effects observed in muscle and cachexia models.
BMP interactions appear weaker with FST-344 than with FST-315, which may preserve more osteogenic signaling while still suppressing muscle-inhibitory ligands. Whether that selectivity translates into a meaningful clinical advantage remains unsettled.
Satellite cell dynamics shift when inhibitory ligand pressure is reduced, with downstream changes that include Smad2/3 dephosphorylation and increased MyoD and myogenin activity. In preclinical systems, this environment also appears to support local IGF-1 signaling within muscle fibers.
What we observe
Measured muscle changes
The following observations derive from peer-reviewed preclinical literature and a limited body of early human data, primarily in disease populations. Aeterna does not prescribe, dispense, or sell. These patterns are presented as a curriculum in mechanism – not as a promise of personal outcome. Individual biology, training status, and baseline muscle architecture all modulate response.
01
Muscle Mass
02
Dystrophic Pathology
03
Immobilization Preservation
04
Satellite Cell Expansion
05
Strength Performance
06
Adipose Modulation
Evidence
The data on growth signals
The evidence base for FST-344 is concentrated in preclinical and early translational research. No large randomized controlled trials in healthy adults exist as of 2025. The studies below represent methodologically rigorous contributions to the mechanistic and translational understanding of this isoform. Aeterna presents them as reference points, not as proof of clinical efficacy in any population.
Systemic Delivery of Follistatin 344 via Recombinant AAV Increases Skeletal Muscle Mass and Strength in Dystrophic Mice
Intramuscular AAV6-FST-344 injection in mdx mice produced significant hypertrophy of treated limb musculature, with a 22% increase in tibialis anterior mass and measurable improvement in tetanic force output at 12 weeks. Fibrosis markers collagen I and III were reduced in treated tissue relative to controls. No adverse cardiac remodeling was observed at the doses studied.
Follistatin Isoform 344 Attenuates Activin-Mediated Muscle Wasting in a Murine Model of Cancer Cachexia
Subcutaneous recombinant FST-344 administered to C26 tumor-bearing mice preserved lean body mass and grip strength relative to vehicle controls. Plasma activin A levels were significantly reduced in treated animals, and Smad2 phosphorylation in gastrocnemius tissue was attenuated by approximately 60%. Survival was modestly extended, though tumor burden was unaffected, suggesting the benefit was purely anti-catabolic.
Intramuscular AAV1-Follistatin Gene Transfer in Becker Muscular Dystrophy: A Phase I/II Open-Label Trial
Six adult males with Becker muscular dystrophy received a single intramuscular injection of AAV1 encoding FST-344. At six months, treated muscles demonstrated a mean 13.5% increase in cross-sectional area by MRI. Two of six participants showed clinically meaningful improvement in the six-minute walk test. No serious adverse events were attributed to the vector or transgene. The study was not powered for efficacy conclusions.
From lyophilized powder to a usable solution.
Peptide
100 mcg · 500 mcg (research-grade lyophilized vials, lot-dependent)
Diluent
Sterile water for injection (SWFI) or PBS pH 7.4 · Do not use acetic acid diluents
Final concentration
10–50 mcg/mL · Gentle swirl only - do not vortex · Allow 5 minutes at room temperature before drawing
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
No human dosing data exist. Research protocols derive from rodent gene-therapy follistatin literature and bodybuilding community reports, with intramuscular site-specific dosing across short cycles.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Store lyophilized vials at −20°C · Stable for up to 24 months unopened under continuous cold-chain conditions
- Reconstituted solution: refrigerate at 2–8°C · Use within 5–7 days · Do not refreeze
- Protect from light at all stages · Amber vials preferred; if clear vials supplied, store in opaque container
- Do not expose to temperatures above 25°C even briefly · Protein denaturation is irreversible and may not be visually apparent
- Avoid repeated freeze-thaw cycles · Aliquot into single-use volumes at reconstitution if multi-dose use is anticipated
Side effects
What members describe
- Injection-site reactions: erythema, mild induration, and transient discomfort reported in gene-therapy trial participants; less characterized for recombinant protein administration
- Theoretical concern for supraphysiological muscle hypertrophy with prolonged use - cardiac muscle is also subject to follistatin-mediated signaling; cardiac monitoring is prudent
- Tendon and connective tissue stress: rapid muscle mass accretion without commensurate tendon adaptation may increase injury risk; progressive loading protocols are advisable
- Immunogenicity: as a recombinant protein, FST-344 may elicit anti-drug antibodies with repeated dosing; clinical significance in humans is not yet characterized
- Reproductive axis effects: follistatin is a physiological regulator of FSH; exogenous FST-344 may suppress FSH signaling - relevant in individuals attempting conception or monitoring gonadal function
Contradictions
Reasons to abstain
- Active malignancy: follistatin and activin signaling intersect with tumor biology in several cancer types; use in oncology patients is not supported by current evidence
- Pregnancy and lactation: no safety data exist; follistatin plays essential roles in embryonic patterning and placental function
- Known hypersensitivity to recombinant proteins or any excipient present in the lyophilized formulation
- Pre-existing cardiac hypertrophy or hypertrophic cardiomyopathy: the cardiac implications of systemic myostatin/activin suppression are not fully characterized
- Concurrent use of anabolic-androgenic steroids or other myostatin-pathway inhibitors without medical supervision - additive hypertrophic effects and unknown interaction profile
Synergies
Best combos for muscle goals
FST-344 addresses the inhibitory ceiling on muscle growth. The companions below address complementary pillars: repair signaling, anabolic priming, and connective tissue integrity. No stack should be assembled without understanding each component individually. Aeterna does not prescribe, dispense, or sell. These pairings reflect mechanistic logic, not clinical protocols.
FAQ
Your questions, patiently answered
Both are isoforms of the same follistatin gene, differing by the presence or absence of a heparin-binding domain encoded by exon 6. FST-315 contains this domain and binds to cell-surface heparan sulfate proteoglycans, concentrating its activity in local tissue. FST-344 lacks this domain and circulates freely in plasma, producing a more systemic inhibitory profile. For muscle applications, FST-344’s broader distribution is generally considered advantageous; for applications where local tissue specificity is desired, FST-315 may be preferred.
The gene therapy trials – including the Nationwide Children’s Hospital work in DMD and the Phase I/II Becker MD study – delivered the FST-344 coding sequence via adeno-associated viral vectors, causing transduced muscle cells to produce the protein endogenously. Recombinant FST-344 protein, administered exogenously, is a pharmacologically distinct approach with a different pharmacokinetic profile, shorter duration of action, and no permanent genomic integration. The mechanistic target is identical; the delivery architecture is not.
Cardiac muscle expresses myostatin and activin receptors, and follistatin signaling does influence cardiac hypertrophy. Preclinical studies have generally not observed adverse cardiac remodeling at therapeutic doses, but the literature is not extensive, and no long-term human cardiac safety data exist. Individuals with pre-existing hypertrophic cardiomyopathy or other structural cardiac conditions should approach this compound with particular caution and appropriate monitoring.
Follistatin is a physiological antagonist of activin, which in turn regulates FSH secretion from the pituitary. Exogenous FST-344 has the potential to suppress FSH, with downstream effects on gonadal function in both sexes. The magnitude of this effect at investigational doses is not well characterized in humans. Individuals monitoring fertility or undergoing reproductive endocrinology evaluation should disclose any FST-344 use to their treating physician.
Serum myostatin levels can be measured via ELISA and may reflect suppression, though assay standardization across laboratories varies. DEXA-derived lean mass is the most practical functional endpoint. Grip dynamometry and validated functional assessments (six-minute walk, stair-climb time) provide additional signal. Serum FSH and LH offer a window into reproductive axis effects. No single biomarker is definitive; a panel approach is more informative.
Meaningful differences exist. Pharmaceutical-grade recombinant proteins undergo rigorous quality control for endotoxin content, glycosylation pattern, aggregation state, and biological activity. Research-grade material varies considerably by vendor and lot. Endotoxin contamination in particular can produce inflammatory responses that confound both safety and efficacy assessment. Sourcing from vendors who provide certificates of analysis with endotoxin testing, mass spectrometry confirmation, and HPLC purity data is the minimum standard for responsible investigational use.
In the same family
Further reading in the curriculum - adjacent monographs.
Sourcing · Independently verified
When you're ready, source thoughtfully.